Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 01, 2021 08:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Appoints Mike Sapieha, Ph.D., as Chief Scientific Advisor

Mike Sapieha brings world-class expertise in aging-related ophthalmologic and neurologic diseases UNITY also names Jason Damiano, Ph.D., as vice president of translational biology and Nathan Guz,...
December 16, 2020 08:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Reports Granting of New Employment Inducement Awards

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of...
December 14, 2020 07:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Announces Appointment of Clinical Development and Industry Veteran Gilmore O’Neill, M.B., to the Board of Directors

Nathaniel E. David, Ph.D., to step down from Management Team, but will remain on UNITY’s Board Changes Reflect Strategic Focus on Clinical Development in Age-Related Diseases of the Eye and Brain ...
November 04, 2020 16:01 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology, Inc. Reports Third Quarter 2020 Financial Results and Clinical Program Updates

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of...
October 12, 2020 08:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema

SAN FRANCISCO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...
September 15, 2020 08:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology

- Corporate restructuring to extend cash runway through mid-2022 and key milestones - - UBX1325 to enter clinical development in patients with diabetic macular edema - SAN FRANCISCO, Calif., Sept. ...
September 04, 2020 08:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology to Participate in Upcoming September Investor Conferences

SAN FRANCISCO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...
August 31, 2020 16:05 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Announces Appointment of Lynne Sullivan as Chief Financial Officer

SAN FRANCISCO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...
August 17, 2020 07:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Announces 12-week data from UBX0101 Phase 2 Clinical Study in Patients with Painful Osteoarthritis of the Knee

UBX0101 failed to meet 12-week primary endpointGuidance for UNITY’s Bcl-xL inhibitor UBX1325 in retinal disease remains unchangedUNITY to focus senescence programs on ophthalmologic and neurologic...
August 04, 2020 16:05 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Announces $80M Debt Financing From Hercules Capital

SAN FRANCISCO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right